Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 4
Submit an article Journal homepage
209
Views
12
CrossRef citations to date
0
Altmetric
Review

Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases

John A Carter Pharmerit International, Bethesda, MD 20814, USA
,
Xiang Ji Pharmerit International, Bethesda, MD 20814, USA
&
Marc F Botteman Pharmerit International, Bethesda, MD 20814, USA. [email protected]
Pages 483-496 | Published online: 09 Jan 2014

References

  • Coleman RE. Bisphosphonates in breast cancer. Ann. Oncol. 16(5), 687–695 (2005).
  • Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 3, CD003474 (2005).
  • Ross JR, Saunders Y, Edmonds PM et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol. Assess. 8(4), 1–176 (2004).
  • Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst. Rev. 4, CD006250 (2006).
  • Penel N, Hollebecque A, Maynou C et al. Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Support. Care Cancer 16(9), 1089–1093 (2008).
  • Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8), 1860–1867 (2007).
  • Woodward E, Jagdev S, McParland L et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1), 160–166 (2011).
  • Ashford RU, Hanna SA, Park DH et al. Proximal femoral replacements for metastatic bone disease: financial implications for sarcoma units. Int. Orthop. 34(5), 709–713 (2010).
  • Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J. Manag. Care Pharm. 16(9), 693–702 (2010).
  • Barton MB, Jacob SA, Gebsky V. Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. Australas. Radiol. 47(3), 274–278 (2003).
  • Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann. Oncol. 17(7), 1072–1082 (2006).
  • Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S. Cost–effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur. J. Health Econ. 12(6), 575–588 (2011).
  • Carter JA, Joshi A, Kaura S, Botteman MF. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and The Netherlands. J. Med. Econ. 14(3), 288–298 (2011).
  • Delea T, Langer C, McKiernan J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67(5–6), 390–396 (2004).
  • Félix J, Andreozzi V, Soares M et al.; Portuguese Group for the Study of Bone Metastases. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health 14(4), 499–505 (2011).
  • Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur. Urol. 43(3), 226–232 (2003).
  • Haley ML, Gerszten PC, Heron DE, Chang YF, Atteberry DS, Burton SA. Efficacy and cost–effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J. Neurosurg. Spine 14(4), 537–542 (2011).
  • Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost–effectiveness analysis. J. Clin. Oncol. 18(1), 72–79 (2000).
  • Ito K, Elkin EB, Girotra M, Morris MJ. Cost–effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann. Intern. Med. 152(10), 621–629 (2010).
  • Joshi AD, Carter JA, Botteman MF, Kaura S. Cost–effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, The Netherlands, and the United kingdom. Clin. Ther. 33(3), 291–304.e8 (2011).
  • Konski A, James J, Hartsell W et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am. J. Clin. Oncol. 32(4), 423–428 (2009).
  • Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 60(5), 1373–1378 (2004).
  • Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J. Urol. 178(4 Pt 1), 1423–1428 (2007).
  • Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am. J. Manag. Care 14(5), 317–322 (2008).
  • Velasco LM, Carreras CL, Antonanzas VF et al. Cost–effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases. Clin. Transl. Oncol. 7, 198–204 (2005).
  • van den Hout WB, van der Linden YM, Steenland E et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost–utility analysis based on a randomized trial. J. Natl Cancer Inst. 95(3), 222–229 (2003).
  • Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost–effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Br. J. Cancer 97(2), 152–161 (2007).
  • Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579–584 (2005).
  • Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184, 162–167 (2010).
  • Denosumab [Package Insert]. Amgen Incorporated, CA, USA (2010).
  • Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813–822 (2011).
  • Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010).
  • Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur. J. Cancer Care (Engl.) 19(6), 755–760 (2010).
  • Krahn M, Ritvo P, Irvine J et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med. Care 41(1), 153–164 (2003).
  • McDonough CM, Tosteson AN. Measuring preferences for cost–utility analysis: how choice of method may influence decision-making. Pharmacoeconomics 25(2), 93–106 (2007).

Websites

  • US FDA CfDEaR. Xgeva BLA 125320/7 Approval Letter. US FDA. 11-18-2010. 4-8-2011.
  • University of York, NHS Centre for Reviews & Dissemination: Systematic reviews CRD’s guidance for undertaking reviews in health care (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.